US EditionFDA APPROVES MERCK’S RSV SHOT DESPITE ALARMING INFANT TRIAL DATA - The HighWire
Summary by The Highwire
Read with caution - this story is only being covered by one news source that has a ‘low factuality’ rating, which means the outlet has a history of poor reporting practices. Learn more about factuality ratings here.1 Articles
1 Articles
All
Left
Center
Right
1
FDA APPROVES MERCK’S RSV SHOT DESPITE ALARMING INFANT TRIAL DATA - The HighWire
Del and Jefferey dive into the troubling numbers behind Merck’s new RSV shot for infants, recently greenlit by the FDA. Trial data revealed higher rates of deaths and severe respiratory illness in vaccinated babies, yet the FDA overlooked this concerning trial data. AIR DATE: June 19, 2025
Coverage Details
Total News Sources1
Leaning Left0Leaning Right1Center0Last UpdatedBias Distribution100% Right
Bias Distribution
- 100% of the sources lean Right
100% Right
R 100%
Factuality
To view factuality data please Upgrade to Premium
